Primary Sclerosing Cholangitis Treatment Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2017-2028)
2.2 Primary Sclerosing Cholangitis Treatment Growth Trends by Region
2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2017-2022)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2023-2028)
2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis Treatment Players by Revenue (2017-2022)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis Treatment Revenue
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2021
3.5 Primary Sclerosing Cholangitis Treatment Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2017-2022)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2023-2028)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2017-2022)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
8.2 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
8.3 Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
9.2 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
9.3 Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size (2017-2028)
10.2 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022)
10.3 Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Detail
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.1.5 Allergan Recent Development
11.2 Glenmark
11.2.1 Glenmark Company Detail
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.2.5 Glenmark Recent Development
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Detail
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.3.5 Impax Laboratories Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.4.5 Mylan Recent Development
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Detail
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.5.5 Teva Pharmaceuticals Recent Development
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Detail
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.6.5 Dr. Falk Pharma Recent Development
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Detail
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.7.5 Daewoong Pharmaceutical Recent Development
11.8 Epic Pharma
11.8.1 Epic Pharma Company Detail
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.8.5 Epic Pharma Recent Development
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Detail
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.9.5 Mitsubishi Tanabe Pharma Recent Development
11.10 Lannett
11.10.1 Lannett Company Detail
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.10.5 Lannett Recent Development
11.11 Bruschettini
11.11.1 Bruschettini Company Detail
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.11.5 Bruschettini Recent Development
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Detail
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.12.5 Shanghai Pharma Recent Development
11.13 Grindeks
11.13.1 Grindeks Company Detail
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.13.5 Grindeks Recent Development
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Detail
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.14.5 Acorda Therapeutics Recent Development
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Detail
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.15.5 Gilead Sciences Recent Development
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Detail
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.16.5 Intercept Pharmaceuticals Recent Development
11.17 Shire Plc
11.17.1 Shire Plc Company Detail
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.17.5 Shire Plc Recent Development
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Detail
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.18.5 NGM Biopharmaceuticals Recent Development
11.19 Conatus Pharmaceuticals
11.19.1 Conatus Pharmaceuticals Company Detail
11.19.2 Conatus Pharmaceuticals Business Overview
11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.19.5 Conatus Pharmaceuticals Recent Development
11.20 Durect Corporation
11.20.1 Durect Corporation Company Detail
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.20.5 Durect Corporation Recent Development
11.21 Sirnaomics
11.21.1 Sirnaomics Company Detail
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.21.5 Sirnaomics Recent Development
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Detail
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Liver Transplantation Operation
Table 3. Key Players of UDCA Drugs
Table 4. Key Players of PSC Drugs
Table 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2017-2022)
Table 9. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2023-2028)
Table 11. Primary Sclerosing Cholangitis Treatment Market Trends
Table 12. Primary Sclerosing Cholangitis Treatment Market Drivers
Table 13. Primary Sclerosing Cholangitis Treatment Market Challenges
Table 14. Primary Sclerosing Cholangitis Treatment Market Restraints
Table 15. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Primary Sclerosing Cholangitis Treatment Market Share by Players (2017-2022)
Table 17. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021)
Table 18. Ranking of Global Top Primary Sclerosing Cholangitis Treatment Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Primary Sclerosing Cholangitis Treatment Product Solution and Service
Table 22. Date of Enter into Primary Sclerosing Cholangitis Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2017-2022)
Table 26. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2023-2028)
Table 28. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2017-2022)
Table 30. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Application (2023-2028)
Table 32. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 42. Allergan Company Detail
Table 43. Allergan Business Overview
Table 44. Allergan Primary Sclerosing Cholangitis Treatment Product
Table 45. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 46. Allergan Recent Development
Table 47. Glenmark Company Detail
Table 48. Glenmark Business Overview
Table 49. Glenmark Primary Sclerosing Cholangitis Treatment Product
Table 50. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 51. Glenmark Recent Development
Table 52. Impax Laboratories Company Detail
Table 53. Impax Laboratories Business Overview
Table 54. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
Table 55. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 56. Impax Laboratories Recent Development
Table 57. Mylan Company Detail
Table 58. Mylan Business Overview
Table 59. Mylan Primary Sclerosing Cholangitis Treatment Product
Table 60. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 61. Mylan Recent Development
Table 62. Teva Pharmaceuticals Company Detail
Table 63. Teva Pharmaceuticals Business Overview
Table 64. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
Table 65. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 66. Teva Pharmaceuticals Recent Development
Table 67. Dr. Falk Pharma Company Detail
Table 68. Dr. Falk Pharma Business Overview
Table 69. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
Table 70. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 71. Dr. Falk Pharma Recent Development
Table 72. Daewoong Pharmaceutical Company Detail
Table 73. Daewoong Pharmaceutical Business Overview
Table 74. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
Table 75. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 76. Daewoong Pharmaceutical Recent Development
Table 77. Epic Pharma Company Detail
Table 78. Epic Pharma Business Overview
Table 79. Epic Pharma Primary Sclerosing Cholangitis Treatment Product
Table 80. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 81. Epic Pharma Recent Development
Table 82. Mitsubishi Tanabe Pharma Company Detail
Table 83. Mitsubishi Tanabe Pharma Business Overview
Table 84. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
Table 85. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 86. Mitsubishi Tanabe Pharma Recent Development
Table 87. Lannett Company Detail
Table 88. Lannett Business Overview
Table 89. Lannett Primary Sclerosing Cholangitis Treatment Product
Table 90. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 91. Lannett Recent Development
Table 92. Bruschettini Company Detail
Table 93. Bruschettini Business Overview
Table 94. Bruschettini Primary Sclerosing Cholangitis TreatmentProduct
Table 95. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 96. Bruschettini Recent Development
Table 97. Shanghai Pharma Company Detail
Table 98. Shanghai Pharma Business Overview
Table 99. Shanghai Pharma Primary Sclerosing Cholangitis TreatmentProduct
Table 100. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 101. Shanghai Pharma Recent Development
Table 102. Grindeks Company Detail
Table 103. Grindeks Business Overview
Table 104. Grindeks Primary Sclerosing Cholangitis TreatmentProduct
Table 105. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 106. Grindeks Recent Development
Table 107. Acorda Therapeutics Company Detail
Table 108. Acorda Therapeutics Business Overview
Table 109. Acorda Therapeutics Primary Sclerosing Cholangitis TreatmentProduct
Table 110. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 111. Acorda Therapeutics Recent Development
Table 112. Gilead Sciences Company Detail
Table 113. Gilead Sciences Business Overview
Table 114. Gilead Sciences Primary Sclerosing Cholangitis TreatmentProduct
Table 115. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 116. Gilead Sciences Recent Development
Table 117. Intercept Pharmaceuticals Company Detail
Table 118. Intercept Pharmaceuticals Business Overview
Table 119. Intercept Pharmaceuticals Primary Sclerosing Cholangitis TreatmentProduct
Table 120. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 121. Intercept Pharmaceuticals Recent Development
Table 122. Shire Plc Company Detail
Table 123. Shire Plc Business Overview
Table 124. Shire Plc Primary Sclerosing Cholangitis TreatmentProduct
Table 125. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 126. Shire Plc Recent Development
Table 127. NGM Biopharmaceuticals Company Detail
Table 128. NGM Biopharmaceuticals Business Overview
Table 129. NGM Biopharmaceuticals Primary Sclerosing Cholangitis TreatmentProduct
Table 130. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 131. NGM Biopharmaceuticals Recent Development
Table 132. Conatus Pharmaceuticals Company Detail
Table 133. Conatus Pharmaceuticals Business Overview
Table 134. Conatus Pharmaceuticals Primary Sclerosing Cholangitis TreatmentProduct
Table 135. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 136. Conatus Pharmaceuticals Recent Development
Table 137. Durect Corporation Company Detail
Table 138. Durect Corporation Business Overview
Table 139. Durect Corporation Primary Sclerosing Cholangitis TreatmentProduct
Table 140. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 141. Durect Corporation Recent Development
Table 142. Sirnaomics Company Detail
Table 143. Sirnaomics Business Overview
Table 144. Sirnaomics Primary Sclerosing Cholangitis TreatmentProduct
Table 145. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 146. Sirnaomics Recent Development
Table 147. Shenzhen HighTide Biopharmaceuticals Company Detail
Table 148. Shenzhen HighTide Biopharmaceuticals Business Overview
Table 149. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis TreatmentProduct
Table 150. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2017-2022) & (US$ Million)
Table 151. Shenzhen HighTide Biopharmaceuticals Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2021 VS 2028
Figure 2. Liver Transplantation Operation Features
Figure 3. UDCA Drugs Features
Figure 4. PSC Drugs Features
Figure 5. Global Primary Sclerosing Cholangitis Treatment Market Share by Application in 2021 & 2028
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Other Case Studies
Figure 9. Primary Sclerosing Cholangitis Treatment Report Years Considered
Figure 10. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Share by Region: 2021 VS 2028
Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2021
Figure 14. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2021
Figure 16. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Primary Sclerosing Cholangitis Treatment Market Share by Country (2017-2028)
Figure 18. United States Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Primary Sclerosing Cholangitis Treatment Market Share by Country (2017-2028)
Figure 22. Germany Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Primary Sclerosing Cholangitis Treatment Market Share by Region (2017-2028)
Figure 30. China Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Primary Sclerosing Cholangitis Treatment Market Share by Country (2017-2028)
Figure 38. Mexico Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Primary Sclerosing Cholangitis Treatment Market Share by Country (2017-2028)
Figure 42. Turkey Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 45. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 46. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 47. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 48. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 49. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 50. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 51. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 52. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 53. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 54. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 55. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 56. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 57. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 58. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 59. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 60. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 61. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 62. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 63. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 64. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 65. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2017-2022)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Industry Market Size
